First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation

Area of Science:

• Nephrology
• Immunosuppression
• Transplantation

Background:

• Thoracic organ transplant recipients often experience compromised kidney function.
• Calcineurin inhibitors (CNIs) are standard immunosuppressants but can impair renal function.
• Alternative immunosuppressive strategies are needed for patients with severe renal dysfunction.

Purpose of the Study:

• To evaluate the safety and efficacy of rapamycin in thoracic organ transplant recipients with severely impaired kidney function.
• To assess the impact of a rapamycin-based immunosuppressive protocol on renal function.
• To gain initial experience with rapamycin in this patient population.

Main Methods:

• Twelve heart transplant patients with serum creatinine > 2.5 mg/dL were included.
• Existing calcineurin inhibitor (cyclosporine A or tacrolimus) was reduced by 50% and rapamycin was added.
• Azathioprine was discontinued, while corticosteroid treatment remained unchanged.

Main Results:

• Kidney function improved within one week of implementing the rapamycin-based protocol.
• Serum creatinine decreased significantly (p = 0.0004) and creatinine clearance increased (p = 0.003).
• Improvements were sustained for 3 months, with no significant changes up to 6 months. Side-effects were linked to rapamycin levels exceeding 12 ng/mL.

Conclusions:

• Partially replacing calcineurin inhibitors with rapamycin provides immediate renal function benefits in transplant patients with impaired kidney function.
• Rapamycin-based immunosuppression is a viable option for thoracic organ transplant recipients with compromised renal function.
• Careful monitoring of rapamycin levels is crucial to minimize side-effects.